follicular lymphoma

Related by string. Follicular Lymphoma * Follicular : follicular NHL . follicular CD# positive . follicular dendritic cells . rituximab refractory follicular / lymphomas . Lymphoma . Lymphomas . LYMPHOMA : cure leukemia lymphoma . Cure leukemia lymphoma . leukemia lymphoma . Mantle Cell Lymphoma * relapsed follicular lymphoma . follicular lymphoma FL . refractory follicular lymphoma *

Related by context. All words. (Click for frequent words.) 69 indolent NHL 67 chronic lymphocytic leukemia CLL 67 metastatic renal cell carcinoma 67 leukemia CLL 66 follicular NHL 66 DLBCL 66 NSCLC 66 CLL 65 lymphomas 65 mRCC 64 cell lymphomas 64 small lymphocytic lymphoma 64 dasatinib 64 cytogenetic responses 64 metastatic colorectal cancer 64 Hodgkin lymphoma NHL 64 glioblastoma 64 renal cell carcinoma 63 metastatic disease 63 advanced NSCLC 63 rituximab 63 differentiated thyroid 63 acute myeloid leukemia AML 63 brain metastases 63 grade gliomas 63 myelodysplastic syndrome MDS 63 pancreatic adenocarcinoma 63 Non Hodgkin lymphoma 63 relapsed refractory 63 acute myelogenous leukemia AML 62 non Hodgkin lymphomas 62 multiple myeloma 62 malignancies 62 nilotinib 62 HER2 positive breast cancer 62 HCV infection 62 bortezomib 62 chronic myeloid leukemia CML 62 cell lymphoma DLBCL 62 KRAS wild 62 breast carcinomas 62 metastatic melanoma 62 chemotherapy regimens 61 chronic lymphocytic leukemia 61 medullary thyroid cancer 61 indolent lymphoma 61 BRAF mutations 61 leukemia AML 61 tumor recurrence 61 cell lymphoma 61 carcinoma 61 chlorambucil 61 taxane therapy 61 Non Hodgkin Lymphoma 61 follicular non 61 glioblastomas 61 hepatocellular carcinoma HCC 61 hepatocellular carcinoma 61 HER2 positive metastatic breast 61 non Hodgkin lymphoma 61 operable breast cancer 61 follicular lymphoma FL 61 metastatic cancer 61 neuroendocrine tumors 61 acute leukemias 61 Chronic Lymphocytic Leukemia CLL 61 non Hodgkin Lymphoma 61 soft tissue sarcomas 61 tyrosine kinase inhibitors 61 MALT lymphoma 61 CVP chemotherapy 61 chronic myelogenous leukemia CML 61 multiple myeloma MM 61 basal cell carcinoma BCC 61 leukemia ALL 60 complete remissions 60 liver metastases 60 castration resistant prostate cancer 60 cell lymphoma CTCL 60 imatinib resistant 60 EGFR mutations 60 malignant pleural mesothelioma 60 CHOP chemotherapy 60 pancreatic NET 60 chemoradiation 60 T#I mutation 60 mycosis fungoides 60 distant metastases 60 Fludara 60 rituximab refractory 60 superficial bladder cancer 60 HNSCC 60 heavily pretreated 60 gastrointestinal stromal tumors 60 recurrent NSCLC 60 Acute Myeloid Leukemia AML 60 FOLFIRI 60 tumor shrinkage 60 B CLL 60 Follicular Lymphoma 60 malignancy 59 topotecan 59 heavily pretreated patients 59 solid tumors 59 bone metastases 59 metastatic RCC 59 imatinib 59 metastatic 59 metastatic lesions 59 medulloblastoma 59 Follicular lymphoma 59 refractory chronic myeloid 59 cutaneous T cell 59 metastatic malignant melanoma 59 hepatocellular cancer 59 stage IIIB 59 histologies 59 bendamustine 59 epithelial tumors 59 lymphoma 59 metastases 59 CLL SLL 59 previously untreated follicular 59 erlotinib 59 astrocytoma 59 locoregional 59 Rituximab 59 remission induction 59 prostate cancer HRPC 59 HRPC 59 evaluable patients 59 lymphoma CTCL 59 oblimersen 59 CLL cells 59 cytogenetic response 59 sorafenib 59 squamous 59 cetuximab 59 prostate cancer CaP 59 metastatic lung cancer 59 acute myeloid leukemia 59 Gleevec resistant 58 glioblastoma multiforme GBM 58 cell carcinoma 58 gefitinib 58 temsirolimus 58 metastatic colon cancer 58 neoadjuvant chemotherapy 58 relapsed refractory multiple myeloma 58 leukemias 58 mCRC patients 58 grade glioma 58 complete cytogenetic 58 recurrent glioblastoma multiforme 58 systemic ALCL 58 trabectedin 58 vinorelbine 58 cisplatin chemotherapy 58 metastatic prostate cancer 58 cell malignancies 58 cancers 58 imatinib Gleevec 58 azacytidine 58 seminoma 58 lupus nephritis 58 metastatic kidney 58 gastrointestinal stromal tumors GIST 58 melanoma 58 mCRC 58 fallopian tube carcinoma 58 alkylating agent 58 hematologic malignancies 58 platinum refractory 58 non metastatic osteosarcoma 58 cell lung cancer 58 stage IIIA 58 KRAS mutations occur 58 Amrubicin 58 CMV disease 58 Waldenstrom macroglobulinemia 58 EGFR inhibitors 58 T#I [002] 58 carboplatin paclitaxel 58 tumors 58 cytotoxic chemotherapy 58 decitabine 58 distant metastasis 58 dasatinib Sprycel 58 Doxil ® 58 Bortezomib 58 gastric cancer 57 relapsed AML 57 GvHD 57 bladder cancers 57 prostate adenocarcinoma 57 HER2 overexpression 57 nonsmall cell lung cancer 57 refractory multiple myeloma 57 Hepatocellular Carcinoma HCC 57 cutaneous melanoma 57 recurrent GBM 57 histologic subtype 57 IMGN# 57 glioma 57 anaplastic 57 malignant gliomas 57 IV melanoma 57 myelofibrosis 57 gastrointestinal stromal tumor 57 renal tumors 57 metastatic breast cancer 57 gemcitabine carboplatin 57 adenocarcinoma 57 Hodgkin lymphoma 57 IIIB NSCLC 57 unresectable stage 57 tumor regression 57 carcinoid 57 colorectal liver metastases 57 GIST 57 WT1 57 patients evaluable 57 sorafenib Nexavar ® 57 gastrointestinal stromal tumor GIST 57 galiximab 57 sarcomas 57 GISTs 57 relapsed MM 57 resistant ovarian cancer 57 fludarabine 57 erlotinib Tarceva ® 57 breast carcinoma 57 NMIBC 57 squamous cell carcinoma 57 follicular lymphomas 57 hepatic metastases 57 invasive candidiasis 57 biologic therapy 57 Chronic lymphocytic leukemia 57 relapsed ovarian cancer 57 squamous cell carcinoma SCC 57 carcinomas 57 relapsing remitting 57 TORISEL 57 temozolomide 57 pancreatic carcinoma 57 invasive aspergillosis 57 basal cell carcinomas 57 bone metastasis 57 squamous cell carcinomas 57 mycophenolate mofetil 57 metastatic renal cell 57 Non Hodgkin 57 imatinib therapy 57 carboplatin 57 TREANDA 57 Xanafide 57 refractory ovarian cancer 56 Fludarabine 56 leukaemias 56 standard chemotherapy regimen 56 lymphocytic leukemia 56 KRAS status 56 hematological cancers 56 sarcomatoid 56 lymph node metastases 56 refractory CTCL 56 Glioblastoma 56 chronic HBV infection 56 preoperative chemotherapy 56 elacytarabine 56 vandetanib 56 bevacizumab Avastin ® 56 docetaxel chemotherapy 56 Burkitt lymphoma 56 Tarceva erlotinib 56 pCR 56 lymphocytosis 56 idarubicin 56 BRAF mutation 56 prostate cancer PCa 56 EGFR mutation 56 cutaneous T 56 Rituxan rituximab 56 relapsed GBM 56 relapsing remitting multiple sclerosis 56 gemcitabine 56 IV NSCLC 56 colorectal cancer CRC 56 refractory CLL 56 receptor tyrosine kinase inhibitor 56 Hodgkin lymphoma HL 56 fluorouracil 56 refractory NSCLC 56 BCR ABL mutations 56 chemoradiotherapy 56 lung metastases 56 grade cervical intraepithelial 56 Mantle Cell Lymphoma 56 refractory indolent non 56 hormone refractory prostate cancer 56 bleomycin 56 Diffuse Large B 56 sarcoma 56 adjuvant therapy 56 azacitidine 56 Glioblastoma Multiforme 56 Rituxan MabThera 56 hepatitis C genotype 56 soft tissue sarcoma 56 renal cell carcinomas 56 gefitinib Iressa 56 metastasis 56 pediatric acute lymphoblastic 56 pegylated liposomal doxorubicin 56 Erlotinib 56 serous ovarian cancer 56 ependymoma 56 acute promyelocytic leukemia APL 56 metastatic GIST 56 CIN3 56 prostate cancer mCRPC 56 FOLFOX4 56 urothelial carcinoma 56 node metastases 56 relapsed multiple myeloma 56 neoadjuvant therapy 56 HER2 positive 56 Chronic Myelogenous Leukemia CML 56 trastuzumab 56 SUTENT 56 neoplasia 56 Cell Lymphoma 56 non squamous 56 SCCHN 56 leukemia APL 56 MGUS 56 indolent follicular non 56 dacarbazine DTIC 56 nonmelanoma skin cancers 56 carcinoid tumors 56 Carboplatin 56 metastatic pancreatic cancer 56 AMN# [001] 56 EGFr 56 splenectomized patients 55 papillary renal cell carcinoma 55 refractory AML 55 medulloblastomas 55 acute lymphoblastic leukemia 55 cytoreduction 55 standard chemotherapy regimens 55 metastatic malignant 55 Cell Lung Cancer 55 chemotherapy regimen 55 gliomas 55 prostate cancers 55 enzastaurin 55 hematologic 55 adalimumab 55 unresectable 55 neuroblastomas 55 mutated KRAS 55 lung cancers 55 chemotherapeutic agent 55 myelofibrosis polycythemia vera 55 gastric cancers 55 postoperative chemotherapy 55 CR CRu 55 Velcade bortezomib 55 sorafenib Nexavar 55 cancer mCRC 55 refractory CML 55 tumor progression 55 prognostic variables 55 chronic HCV 55 axitinib 55 malignant melanoma 55 anticancer therapy 55 erlotinib Tarceva 55 ZEVALIN 55 myelodysplastic syndromes MDS 55 prostate cancer CRPC 55 HSCT 55 recurrent colorectal cancer 55 relapsed SCLC 55 relapsed CLL 55 leiomyosarcoma 55 metastatic bladder 55 bevacizumab 55 hormone receptor positive 55 molecularly targeted 55 cutaneous squamous cell carcinoma 55 ponatinib 55 systemic lupus erythematosus 55 PCa 55 febrile neutropenia 55 posaconazole 55 ovarian carcinoma 55 Waldenstrom Macroglobulinemia 55 MabCampath 55 Carcinoma 55 cell carcinomas 55 nonmetastatic 55 acute lymphoblastic 55 squamous cell cancer 55 grade dysplasia 55 Taxotere ® 55 synovial sarcoma 55 neuroendocrine cancers 55 daunorubicin 55 HER2 negative 55 partial remissions 55 myeloma 55 colorectal cancer 55 OncoVEX GM CSF 55 IV metastatic melanoma 55 free survival PFS 55 panobinostat 55 YONDELIS 55 Acute Myelogenous Leukemia AML 55 EGFR TKI 55 anti TNF 55 CTCL 55 TACE 55 dacarbazine 55 antiangiogenic therapy 55 premalignant lesions 55 PCNSL 55 trastuzumab Herceptin ® 55 systemic lupus erythematosus SLE 55 BiovaxID 55 docetaxel Taxotere R 55 cell lymphoma ALCL 55 bortezomib Velcade 55 diagnosed multiple myeloma 55 pomalidomide 55 lung adenocarcinoma 55 Solid Tumors criteria 55 mitomycin 55 recurrent glioblastoma 55 Pemetrexed 55 papillary 55 glioblastoma tumors 55 cediranib 55 candidemia 55 myelodysplastic syndromes 55 allograft rejection 55 Acute Myeloid Leukemia 55 cell acute lymphoblastic 54 recurrent glioblastoma multiforme GBM 54 gemcitabine Gemzar 54 dasatinib Sprycel ® 54 thalidomide Thalomid 54 malignant neoplasms 54 taxanes 54 evaluable 54 Non Hodgkin Lymphomas 54 ovarian cancers 54 BCG refractory 54 sunitinib 54 metastatic CRC 54 hypomethylating agents 54 CYT# potent vascular disrupting 54 biochemical recurrence 54 epirubicin 54 allogeneic bone marrow 54 HCV genotype 1 54 gemcitabine chemotherapy 54 BCR ABL 54 RECIST criteria 54 mutated KRAS gene 54 lung tumors 54 chronic myelogenous leukemia 54 anti angiogenic therapy 54 lobular carcinoma 54 HGS ETR1 54 cell lymphoma MCL 54 Revlimid lenalidomide 54 Soft Tissue Sarcoma 54 OMAPRO 54 CML CP 54 CD# mAb 54 CCyR 54 stage IIIb IV 54 blinatumomab 54 anti angiogenic agents 54 Response Evaluation Criteria 54 invasive breast cancer 54 lung metastasis 54 breast tumors 54 panitumumab 54 precancerous cervical lesions 54 VFEND 54 plus dexamethasone 54 relapsed Acute Myeloid 54 abiraterone 54 castrate resistant 54 chemotherapies 54 gastric adenocarcinoma 54 tyrosine kinase inhibitors TKIs 54 severe sepsis 54 DMARDs 54 ixabepilone 54 cervical intraepithelial neoplasia 54 5-FU/LV 54 Gorlin syndrome 54 chemotherapeutic regimen 54 tumors GIST 54 pertuzumab 54 vismodegib 54 locoregional recurrence 54 predictive biomarker 54 taxane chemotherapy 54 cholangiocarcinoma 54 myeloid leukemia 54 histological subtype 54 pancreatic cancers 54 hematological malignancy 54 T#I mutant 54 myeloablative 54 chemotherapeutic regimens 54 bevacizumab Avastin 54 activating mutations 54 malignant tumors 54 recurrent ovarian cancer 54 acute GvHD 54 rituximab Rituxan 54 Epratuzumab 54 S. aureus infections 54 chemotherapy docetaxel 54 pemetrexed 54 acute leukemia 54 locoregional disease 54 Toxicities 54 glioblastoma GBM 54 micrometastases 54 FOLFOX 54 Metastatic Colorectal Cancer 54 Ph + ALL 54 HCV infected 54 colorectal tumors 54 astrocytomas 54 peritoneal carcinomatosis 54 subtype 54 Cutaneous T 54 blastic phase 54 FluCAM 54 BEXXAR 54 metastatic colorectal 54 MCyR 54 non squamous NSCLC 54 peginterferon 54 cell chronic lymphocytic 54 thymoma 54 resectable 54 osteosarcomas 54 Metastatic 54 advanced adenomas 54 EGFR tyrosine kinase inhibitors 54 MabThera 54 MGd 54 non metastatic resectable 54 endometrial cancers 54 bortezomib Velcade R 54 CaP 54 Kit CD# positive 54 pegfilgrastim 54 uveal melanoma 54 plasma uric acid 54 squamous cell lung cancer 54 stage IIIb 54 situ CIS 54 Ceflatonin 54 refractory 54 basal cell nevus syndrome 54 lymphoma subtypes 54 indolent lymphomas 54 neoadjuvant treatment 54 invasive fungal infection 54 acute promyelocytic leukemia 54 liposomal doxorubicin 54 Cholangiocarcinoma 54 nasopharyngeal cancer 54 nasopharyngeal carcinoma 54 Gleevec imatinib 54 Genasense ® 54 Fludara ® 54 Folfox 54 invasive ductal 54 HBeAg negative 54 intestinal metaplasia 54 Anaplastic 54 MAGE A3 53 relapsed follicular 53 non hodgkin lymphoma 53 refractory cutaneous T 53 relapsing remitting MS 53 Non Hodgkins lymphoma 53 eribulin mesylate 53 trans retinoic acid 53 cilengitide 53 myeloma cells 53 refractory chronic lymphocytic 53 hormone refractory metastatic prostate 53 pancreatic neuroendocrine tumors 53 autologous stem cell 53 palifosfamide 53 Acute lymphoblastic leukemia 53 AP# [003] 53 arsenic trioxide 53 xenograft models 53 colorectal carcinoma 53 BRAF inhibitor 53 low dose cytarabine 53 Gleevec imatinib mesylate 53 REVLIMID 53 epithelial ovarian cancer 53 HBeAg positive 53 hA# 53 anti leukemic 53 rituximab monotherapy 53 histological subtypes 53 Hodgkin Lymphoma 53 metastatic gastric 53 grade cervical dysplasia 53 depsipeptide 53 essential thrombocythemia 53 Imatinib 53 Relapsed Refractory 53 complete cytogenetic response 53 malignant lymphoma 53 EGFR 53 disease progression 53 Proxinium TM 53 KRAS mutant tumors 53 cabazitaxel 53 CBLC# 53 obatoclax 53 refractory acute myeloid 53 osteosarcoma 53 CIN2 + 53 TKI therapy 53 systemic anaplastic large 53 SSc 53 prior chemotherapy regimens 53 cetuximab Erbitux 53 GBM tumors 53 myelofibrosis MF 53 antitumor effect 53 VELCADE 53 placebo dexamethasone 53 adriamycin 53 adenocarcinomas 53 liposarcoma 53 refractory metastatic colorectal cancer 53 imatinib Gleevec ® 53 cytarabine 53 carfilzomib 53 Metastatic breast cancer 53 tanespimycin 53 pleural mesothelioma 53 squamous cell 53 Gefitinib 53 EpCAM 53 amrubicin 53 myeloproliferative disorders 53 cyclophosphamide doxorubicin vincristine 53 prednisolone chemotherapy 53 cisplatin 53 AVASTIN 53 Flu Cy 53 Nexavar sorafenib 53 basal cell carcinoma 53 ABVD 53 antitumor activity 53 pazopanib 53 VIDAZA 53 Cloretazine 53 Renal Cell Carcinoma RCC 53 surrogate endpoint 53 docetaxel 53 papillary RCC 53 KRAS mutant 53 sustained virological response 53 metastatic tumors 53 anthracycline containing 53 Kaposi sarcoma 53 malignant fibrous histiocytoma 53 PI3K/Akt pathway inhibitor 53 AA amyloidosis 53 ovarian tumors 53 completely resected 53 dose cohorts 53 PARP inhibitors 53 colorectal cancers 53 Myelodysplastic Syndrome MDS 53 docetaxel Taxotere ® 53 Alemtuzumab 53 CVP cyclophosphamide vincristine 53 GVHD 53 Cytoxan 53 achieved sustained virological 53 microbiological eradication 53 urothelial bladder cancer 53 tumor 53 PLX# 53 BEACOPP 53 cervical lesions 53 lymphovascular invasion 53 cisplatin resistant 53 HCV 53 ALCL 53 Omacetaxine 53 recurrent genital herpes 53 relapsing multiple sclerosis 53 Dasatinib 53 radioimmunotherapy 53 adenoma 53 chemotherapeutic agents 53 micafungin 53 clinically localized prostate 53 allogeneic stem cell 53 paclitaxel Taxol 53 OPAXIO 53 transitional cell carcinoma 53 certolizumab 53 chronic GVHD 53 relapsed leukemia 53 Myelofibrosis 53 cervical carcinoma 53 therapeutic regimens 53 acute myeloid 53 lymphoid 53 IV malignant melanoma 53 FOLFIRI alone 53 Torisel 53 Gemzar ® 53 EGFR expressing 53 bronchogenic carcinoma 53 imetelstat 53 Halaven 53 anterior uveitis 53 intravenous belinostat 53 Myelodysplastic Syndrome 53 diagnosed glioblastoma multiforme 53 vemurafenib 53 chronic hepatitis B 53 hepatocellular carcinomas 53 5 FU 53 anthracycline taxane 53 Nilotinib 53 cyclophosphamide 53 subependymal giant cell 53 Zolinza 53 chronic myeloid leukemia 53 HDACi 53 atypical hemolytic uremic syndrome 53 MabThera Rituxan 53 nucleoside analogues 53 prostatic adenocarcinoma 53 histologically confirmed 53 FOLFIRINOX 53 HBeAg positive patients 53 prostate carcinoma 53 Tamibarotene 53 alkylating agents 53 Trastuzumab 53 mucinous 53 familial amyloidotic polyneuropathy FAP 53 papillary thyroid carcinoma 53 tipranavir ritonavir 53 anti angiogenic drugs 53 IGF 1R 53 Irinotecan 52 Sorafenib 52 tyrosine kinase inhibitor 52 achieved sustained virologic 52 nab paclitaxel 52 imatinib mesylate Gleevec 52 underwent resection 52 mapatumumab 52 familial ALS 52 hypereosinophilic syndrome 52 biliary tract cancer 52 CRp 52 PTLD 52 ER CHOP 52 breast cancer subtypes 52 sunitinib malate 52 BRAF V#E 52 severe oral mucositis 52 mesotheliomas 52 predictive biomarkers 52 breast cancers 52 TNF antagonist 52 Herceptin trastuzumab 52 achieved CCyR 52 renal carcinoma 52 etoposide 52 anaplastic astrocytoma 52 metastatic NSCLC 52 factor receptor EGFR 52 relapsed 52 Wilms tumor 52 stage IIIB IV 52 thyroid cancers 52 EGFR mutation positive 52 endocrine therapy 52 olaparib 52 HER2 52 KRAS mutations 52 endometrial carcinoma 52 PSADT 52 BRCA deficient 52 ALK inhibitor 52 pan HDAC inhibitor 52 Chronic lymphocytic leukemia CLL 52 chemoresistance 52 carcinoid cancer 52 Lymphomas 52 squamous cell cancers 52 eribulin 52 aHUS 52 Stage IIIb 52 raltegravir 52 NPM1 52 cystectomy 52 neoadjuvant 52 pulmonary metastases 52 malignant lesions 52 gemcitabine Gemzar ® 52 pT3 52 advanced nonsquamous NSCLC 52 Adjuvant chemotherapy 52 smoldering myeloma 52 metastatic neuroendocrine tumors 52 vinca alkaloids 52 brain tumor glioblastoma multiforme 52 MDS AML 52 liver metastasis 52 fluoropyrimidine 52 paclitaxel Taxol ® 52 radical nephrectomy 52 metastatic cancers 52 vinca alkaloid 52 dose cytarabine 52 5 Fluorouracil 52 histologic 52 Seliciclib 52 SPRYCEL ® 52 ganetespib 52 malignant lymphomas 52 cytarabine daunorubicin 52 actinic keratosis 52 metastatic HRPC 52 neuroendocrine carcinoma 52 melanomas 52 HBeAg 52 ADPKD 52 HER2 + 52 mTOR inhibitors 52 achieve sustained virologic 52 relapsing MS 52 lymphoid malignancies 52 KRAS mutation 52 irinotecan 52 concurrent chemoradiation 52 EGFR receptor 52 Ewing sarcoma 52 iniparib 52 prostate tumors 52 BRAF gene 52 fulvestrant 52 Annamycin 52 tumor regressions 52 dexamethasone Decadron 52 Amigal 52 crizotinib PF # 52 BCCs 52 neuroblastoma tumors 52 tumor metastases 52 neoplasm 52 NRTIs 52 HER2/neu 52 interferon ribavirin 52 Malignant Melanoma 52 alvespimycin 52 metastatic colorectal carcinoma 52 metastatic hormone refractory 52 relapsing remitting MS RRMS 52 antibody MAb 52 estramustine 52 pT2 52 Nexavar tablets 52 forodesine 52 SUVmax 52 rhabdomyosarcoma 52 imatinib resistance 52 remission CR 52 HPV# 52 myelodysplastic syndrome 52 epithelioid 52 nodular partial response 52 invasive lobular carcinoma 52 biochemical relapse 52 GNAQ 52 hematologic toxicity 52 TEMODAL 52 Non Hodgkins Lymphoma 52 Xcytrin 52 baseline LDH 52 imipenem 52 Ceplene/IL-2 52 GBMs 52 refractory Hodgkin lymphoma 52 malignant growths 52 relapsed mantle 52 malignant pancreatic 52 GIST tumors 52 IMC A# 52 Chronic Myeloid Leukemia 52 leukemic stem cells 52 trastuzumab Herceptin R 52 ZACTIMA 52 mitomycin C 52 Bcr Abl mutations 52 polycythemia vera PV 52 relapsed Hodgkin lymphoma 52 hematological malignancies 52 urothelial cancer 52 Bevacizumab 52 Vectibix 52 Basal cell 52 colon cancers 52 lymphocytic 52 rindopepimut 52 ErbB2 positive 52 lymph node metastasis 52 hormone deprivation 52 Myelodysplastic syndromes MDS 52 CIMZIA ™ 52 autologous transplants 52 tigecycline 52 docetaxel Taxotere 52 virological response 52 medically inoperable 52 lenalidomide Revlimid R 52 allogeneic HSCT 52 adjuvant chemotherapy 52 inoperable pancreatic cancer 52 chemo radiotherapy 52 elotuzumab 52 Campath alemtuzumab 52 Aflibercept 52 recurrent metastatic 52 5FU 52 carcinoids 52 haematological cancers 52 Pixantrone 52 metachronous 52 transplantation HCT 52 HCV SPRINT 52 DFMO 51 interferon 51 zalutumumab 51 pain palliation 51 ZOLINZA 51 HBeAg negative patients 51 allogeneic transplantation 51 RECIST Response Evaluation Criteria 51 dosing cohort 51 malignant ascites 51 CCR5 tropic HIV 51 lamivudine refractory patients 51 B lymphocytes 51 sunitinib Sutent 51 phase IIb clinical 51 Kantarjian 51 EGF receptor 51 doxorubicin Adriamycin 51 HER2 positive cancers 51 romiplostim 51 NovoTTF 51 Neoadjuvant 51 PNET 51 Paraplatin ® carboplatin 51 CsA 51 FOLPI 51 achieved PASI 51 Retreatment 51 lymph node involvement 51 virologic response 51 vWD 51 papillary thyroid cancer 51 Pertuzumab 51 HCV infections 51 ccRCC 51 huN# DM1

Back to home page